Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
EGHT 8x8 Inc
REGI Renewable Energy Group Inc
MCK Mckesson Corp
CNBX Cannabics Pharmaceuticals Inc
BLK BlackRock Inc
FNMA Federal National Mortgage Association
MPW Medical Properties Trust Inc
PSXP Phillips 66 Partners LP
EQ Equillium Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

Cardiovascular Drugs Market to Exhibit a CAGR of 3.8% and Reach USD 63.96 Billion by 2026; Increasing Prevalence of Cardiovascular Diseases to Augment Growth, says Fortune Business Insights

5:42 am ET September 16, 2020 (Globe Newswire) Print

Global cardiovascular drugs market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth of the cardiovascular drugs market.

According to the American Heart Association, Cardiovascular disease (CVD) accounted for 840,678 deaths in the US in 2016, approximately 1 of every 3 deaths. Also, between 2013 and 2016, 121.5 million American adults had some form of cardiovascular disease. These cardiovascular drugs market trends, along with the innovation and development of new drugs, will foster the growth of the market.

Moreover, In 2014, a study was conducted by the American Heart Association, cardiovascular disease accounted for more than 17.6 million deaths per year in 2016 and is likely to grow to more than 23.6 million by 2030.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiovascular-drugs-market-100379

Highlights of the Report:

-- Analysis of the impact of Covid-19 that the market would face in the near future.

-- In-depth analysis of the growth drivers and obstacles.

-- Profile of all the companies operating in the market.

-- Elaborate data about the dominating region.

-- Competitive landscape consisting of mergers & acquisitions, investments, partnerships, new product launches, opening of new facilities, and new contracts.

As per the report, published by Fortune Business Insights, titled "Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), By Disease Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026" the market was at USD 47.29 billion in 2018.

The report offers dynamic insights into the global cardiovascular drugs market, covering growth prospects, market development potential, supply and demand, profitability, and other important aspects. It is considered to be reliable source of information along with the data on the market trends.

The researchers and analysts have prepared it with an advanced research methodology and authentic primary and secondary sources of market statistics and data. Readers are provided with a clear understanding of the current and future situations of the market based on revenue, shares, trends, technology, advancements and innovations, prevailing factors and restricting factors.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-drugs-market-100379

Growing Need for Advanced and Effective Drugs to Propel Growth

The increasing demand for effective drugs and therapy is expected to aid the growth of the market. The rising R&D investment for innovative drugs and cardiovascular therapeutics will further accelerate the growth of the market. The launch of novel therapies by key players is likely to create growth opportunities for the market.

For instance, Novartis AG and Blackstone's Life Sciences announced the launch of Anthos Therapeutics for the development of cardiovascular drugs as there are large unmet needs for next-generation anti-thrombotic therapies in patients.

New Product Launches will Propel Growth

India based Natco Pharma announced the launch of the generic version of valsartan-sacubitril, a cardiovascular drug for the treatment of congestive heart failure. Novartis AG holds the patent in India for valsartan-sacubitril called Vymada. The launch of the new drug will create growth opportunities for the market in the foreseeable future.

Furthermore, increasing awareness regarding cardiovascular health and the surge in product launches will boost cardiovascular drugs market growth. The introduction of several advanced drugs addressing the diverse treatment needs of cardiovascular diseases will further bolster the growth of the market.

Quick Buy - Cardiovascular Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100379

For instance, Bristol-Myers Squibb Company and Pfizer Inc. introduced a cardiovascular drug called Eliquis (apixaban), which now has the highest sales and is demonstrated to be superior in terms of risk reductions compared to other drugs in the market.

Some of the Major Companies Present in the Global Cardiovascular Drugs Market Include:

-- Bristol-Myers Squibb Company

-- Pfizer Inc.

-- Bayer AG

-- Janssen Pharmaceuticals, Inc.

-- AstraZeneca

-- Sanofi

-- Novartis AG

-- Merck & Co., Inc.

-- Gilead Sciences, Inc.

-- F. Hoffmann-La Roche Ltd

-- Others

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiovascular-drugs-market-100379

Cardiovascular Drugs Market Segmentations:

By Drug Type

? Antihypertensive

? Antihyperlipidemic

? Anticoagulants

? Antiplatelet Drugs

? Others

By Disease Indication

? Hypertension

? Hyperlipidemia

? Coronary Artery Disease

? Arrhythmia

? Others

By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? Others

By Geography

? North America (U.S. and Canada)

? Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

? Latin America (Brazil, Mexico, and Rest of Latin America)

? Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/cardiovascular-drugs-market-100379

Have a Look at Related Reports:

Cardiovascular Stents Market Share and Global Trend By Product Type (Coronary Stenting, Peripheral Stenting), Stent Type (Drug Eluting Stents (DES), Bioresorbable Stents, Bare Metal Stents & Others), Disease Indication (Venous Disease, Arterial Disease), End User and Geography Forecast by 2025

Cardiac Biomarkers Market Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027

Asthma Treatment Market Share & Industry Analysis, By Treatment (Long-Term Control Medications, and Quick-Relief Medications), By Route of Administration (Injectable, Oral, and Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2020-2027

Legionella Testing Market Share & Industry Analysis, By Type (Culture Media, Urine Antigen Testing (UAT), Polymerase Chain Reaction (PCR), Serology, and Direct Fluorescent Antibody (DFA) test; By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2020-2027

Alopecia Treatment Market Share & Industry Analysis, By Route of Administration (Topical, Injectable, Oral), By Gender Type (Male, Female), By Age Group (Below 18 years, 18 - 34 Years, 35 - 49 Years, Above 50 Years), By End User and Regional Forecast, 2020-2027

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/cardiovascular-drugs-market-9382

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.